Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Market Analysis
  • Published:

Alzheimer disease: progress or profit?

Nature Medicine volume 12, pages 780–784 (2006) Cite this article

View saved research

Alzheimer disease is the most common cause of dementia. According to the World Health Organization, an estimated 37 million people worldwide currently have dementia; Alzheimer disease affects about 18 million of them1.

Increasing age is the greatest risk factor for Alzheimer disease. Its prevalence approximately doubles every five years after the age of 60—one in 10 individuals over 65 years and nearly half of those over 85 are affected by the disease. So, although the incidence rate of Alzheimer disease is not thought to be changing, Alzheimer disease poses one of the greatest threats to the future of healthcare systems, owing to the anticipated demographic shift to an aging population—the number of people worldwide above the age of 60 years is expected to double over the next 25 years.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Image
Figure 2: Actual and estimated financial costs of Alzheimer disease in the US6.
Image

Subjects

References

  1. Vas, C.J. et al. Alzheimer's Disease: The Brain Killer World Health Organization. (2001).

  2. Herbert, L.E., Beckett, L.A., Scherr, P.A. & Evans, D.A. Alzheimer. Dis. Assoc. Disord. 15, 169–173 (2001).

    Article  Google Scholar 

  3. Alzheimer's Disease International. Factsheet 3: The prevalence of dementia. http://www.alz.co.uk/adi/pdf/3preval.pdf (1999).

  4. National Institute on Aging, National Institutes of Health. 2001–2002 Alzheimer's Disease Progress Report. National Institutes of Health publication number 03-5333, p. 2 (July 2003).

  5. Alzheimer's Disease Research, Prevention and Care Act of 2003, 108th Congress, 1st Session S.566 in the Senate of the United States (2003).

  6. Lewin Group. Saving Lives, Saving Money: Dividends for Americans Investing in Alzheimer Research. (Washington, DC, 2004).

  7. Hodes, Nat. Med. 770–773 (2006).

  8. Gearing, M. et al. Neurology 45, 461–466 (1995).

    Article  CAS  Google Scholar 

  9. Lanctot, K.L. et al. CMAJ 169, 557–564 (2003).

    PubMed  PubMed Central  Google Scholar 

  10. Farlow, M.R. Int. J. Clin. Pract. Suppl. 127, 37–44 (2002).

    CAS  Google Scholar 

  11. Alzheimer's Association Fact Sheet: FDA-approved cholinesterase inhibitors. http://www.alz.org/Resources/FactSheets/FS_Cholinesteraseinhibtors.pdf (2005).

  12. Tabet, N., Birks, J. & Grimley Evans, J. Cochrane Database Syst. Rev. 4, CD002854 (2000).

    Google Scholar 

  13. Miller, E.R. et al. Ann. Intern. Med. 142, 37–46 (2005).

    Article  CAS  Google Scholar 

  14. Tariot, P.N. & Federoff, H.J. Alzheimer Dis. Assoc. Disord. 17 Suppl 4, S105–S113 (2003).

    Article  CAS  Google Scholar 

  15. Birks, J. Cochrane Database Syst. Rev. 1, CD005593 (2006).

    Google Scholar 

  16. Schechter, L.E. et al. J. Pharmacol. Exp. Ther. 314, 1274–1289 (2005).

    Article  CAS  Google Scholar 

  17. Nicoll, J.A. et al. Nat. Med. 9, 389–390 (2003).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wood Mackenzie, London, EC2N 1HN, UK

    Claire Mount & Christian Downton

Authors
  1. Claire Mount
    View author publications

    Search author on:PubMed Google Scholar

  2. Christian Downton
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Claire Mount.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mount, C., Downton, C. Alzheimer disease: progress or profit?. Nat Med 12, 780–784 (2006). https://doi.org/10.1038/nm0706-780

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nm0706-780

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing